Acute lymphoblastic leukemia of adulthood: Progress or not?

Current Treatment Options in Oncology

Volumn 12, Issue 4, 2011, Pages 303-311

  Wiernik, Peter H ^a,b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; AURORA KINASE INHIBITOR; BLINATUMOMAB; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; KW 2449; MERCAPTOPURINE; METHOTREXATE; OZOGAMICIN; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; AVASCULAR NECROSIS; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MOLECULAR TARGETED THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; RECURRENCE;

EID: 84855896226     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0167-z     Document Type: Article

References (42)

1. Esterhay Jr RJ, Wiernik PH, Grove WR, et al. Moderate dose methotrexate, vincristine, asparaginase, and dexamethasone for treatment of adult acute lymphocytic leukemia. Blood. 1982;59:334-45. (Pubitemid 12172024)
2. Wiernik PH, Dutcher JP, Paietta E, et al. Long-term follow-up of treatment and potential cure of adult acute lymphocytic lkeukemia with MOAD: A nonanthracycline containing regimen. Leukemia. 1993;7:1236-41. (Pubitemid 23256475)
3. Hui L, Wiernik PH. Avascular necrosis of bone after adult acute lymphocytic leukemia treatment with methotrexate, vinvristine, L-asparaginase, and dexamethasone (MOAD). Am J Hematol. 1996;52:184-8. (Pubitemid 26254853)
4. Wiernik PH, Cassileth PA, Leong T, et al. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone cytarabine and 6-thioguanine) in acute lymphoblastic leukemia with long-term follow- up: An Eastern Cooperative Oncology Group study (E3486). Leuk Lymphoma. 2003;44:1515-21. (Pubitemid 36833965)
5. Morris K, Weston H, Mollee P, et al. Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionation cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: Results from an Australian population. Leuk Lymphoma. 2011;52:85-91.
6. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG 2993. Blood. 2005;106:3760-7. (Pubitemid 41739010)
7. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the international ALL trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827-33. (Pubitemid 351451489)
8. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: Results from the international ALL trial MRC UKALLXII/ECOG2993. Blood. 2009;113:4489-96.
9. Patel B, Richards SM, Rowe JM, et al. High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: A UKALL XII analysis. Leukemia. 2008;22:308-12. (Pubitemid 351250536)
10. Bishop MR, Logan BR, Grandham S, et al. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: A comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008;41:635-42. (Pubitemid 351524002)
11. Paulson K, Szwajcer D, Seftel MD. The role of allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. Transfus Apher Sci. 2011;44:197-203.
12. Juliusson G, Karlsson K, Lazarevic VL, et al. Hematopoietic stem cell transplantation rates and longterm survival in acute myeloid and lymphoblastic leukemia: Real-world population-based data from the Swedish acute leukemia registry 1997-2006. Cancer 2011;117:4238-46.
13. Marks DI, Pérez WS, He W, et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood. 2008;112:426-34.
14. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): Analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189-97. (Pubitemid 46572503)
15. Mansour MR, Sulis ML, Duke V, et al. Prognostic implications of NOTCH2 and FBXW7 mutations in adults with T-cell lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol. 2009;27:4352-6.
16. Hunault-Berger M, Lequay T, Thomas X, et al. A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: TheGRALL study. Haematologica. 2011;96:245-52.
17. Karbasian-Esfahani M, Wiernik PH, Novik Y, et al. Idarubicin and standard- dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. Cancer. 2004;101:1414-9. (Pubitemid 39180397)
18. Wang H, Chen XQ, Geng QR, et al. Induction therapy using the MRC UKALLXII/ECOG E2993 protocol in Chinese adults with acute lymphoblastic leukemia. Int J Hematol. 2011;94:163-68.
19. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); analysis of UKALL12/ECOG 2993 study. Blood. 2007;109:944-50. (Pubitemid 46220637)
20. Faderl S, Thomas DA, O'Brien S, et al. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011;11:54-9.
21. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: Clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALLXII/ECOG 2993). Blood. 2009;114:5136-45.
22. Al-Ameri A et al. Hyper-CVAD plus nelarabine in the treatment of newly diagnosed patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL). J Clin Oncol. 2011;29:432s.
23. Samon JB et al. Reversal of glucocorticoid resistance by the g-secretase inhibitor PF-03084014 in T-cell acute lymphoblastic leukemia. J Clin Oncol. 2011;29:597s.
24. Tosello V, Mansour MR, Barnes K, et al. WT1 mutations in T-ALL. Blood. 2009;114:1038-45.
25. Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42:338-42.
26. Paietta E, Ferrando AA, Neuberg D, et al. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemia. Blood. 2004;104:558-60. (Pubitemid 38900041)
27. Litzow MR, Lee S, Bennett JM, et al. A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. Haematologica. 2006;91:1105-8. (Pubitemid 44204778)
28. Domenech C, Thomas X, Chabaud S, et al. L-asparaginase loaded red blood cells in refractory or re- lapsing acute lymphoblastic leukaemia in children and adults: Results of the GRASPALL 2005-01 randomized. Br J Haematol. 2011;153:58-65.
29. Advani AS, Gundacker HM, Sala-Torra O, et al. Southwest oncology group study SO530: A phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. Br J Haematol. 2010;15:430-4.
30. Sun L, Wang Q, Liu X, et al. Anti-cancer effects of 20 (S)-protopanoxadiol on human lymphoblastic leukemia cell lines Reh and RS4;11. Med Oncol. 2011;28:813-21.
31. Chao MP, Alizadeh AA, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Canc Res. 2011;71:1374-84. Describes a potentially new therapy for adult ALL.
32. Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011; 29:2493-8. Describes a potentially new post-induction therapy with the potential for eradicating minimal residual disease in adult ALL.
33. Jabbour E et al. Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia. J Clin Oncol. 2011;29:420s.
34. Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia: Current treatment and future perspectives. Cancer. 2011;117:1583-94.
35. Jaso J, Thomas DA, Cunningham K, et al. Prognostic significance of immunophenotypic and karyotypic features of philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Cancer 2011;117:4009-17.
36. Juric D, Lacayo NJ, Ramsey MC, et al. Differential gene expression patterns and interaction networks in BCR-ABL -positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol. 2007;25:1341-9. (Pubitemid 46706880)
37. Nguyen T, Dai Y, Attkinsson E, et al. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res. 2011; 17:3219-32. Describes a potentially new therapy that may enhance the activity of thymidine kinase inhibitors in Philadelphia chromosome-positive adult ALL.
38. Patel SB, Gojo I, Tidwell ML, et al. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma 2011;52:1211-14.
39. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29:532-43.
40. Litzow MR. Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults. Drugs. 2011;71:415-42.
41. Rowe JM. Optimal management of adults with ALL. Br J Haematol. 2009;144:468-83.
42. Narayanan S, Shami PJ. Treatment of acute lymphoblastic leukemia in adults. Crit Rev Oncol Hematol. 2011, in press.